文献速递肿瘤 PET/CT核素与放射性配体治疗

[68Ga]Ga-NODAGA-ADAPT6 作为一种新型 HER2 靶向 PET 示踪剂用于乳腺癌显像与治疗监测的研发与临床评价

Development and clinical evaluation of [68Ga]Ga-NODAGA-ADAPT6 as a novel HER2-targeted PET radiotracer for breast cancer imaging and treatment monitoring.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-04-21

研究对 ADAPT6 进行 N 端(GHEHEHEDANS)与 C 端(GSSC)修饰并制备 [68Ga]Ga-NODAGA-ADAPT6,在 HCC1954(HER2 阳性)与 MDA-MB-468(HER2 阴性)荷瘤小鼠中完成体内代谢与生物分布研究,并经伦理批准和知情同意对 22 例乳腺癌患者行 PET 显像。示踪剂放化纯度超过 99%,在体内高度稳定;临床 PET 图像中原发与转移灶的摄取水平与病理分析的 HER2 表达状态相关性良好。

要点

  • 示踪剂放化纯度超过 99%,体内稳定性高。
  • HCC1954 肿瘤明显摄取,曲妥珠单抗阻断 HER2 后摄取显著降低。
  • 22 例乳腺癌患者 PET 摄取与病理 HER2 表达状态相关性良好。

核心结论

  • [68Ga]Ga-NODAGA-ADAPT6 具有良好的药代动力学性质和对 HER2 表达病灶的高特异性,有望用于区分乳腺癌不同 HER2 表达水平并辅助个体化治疗策略。

研究设计与样本

  • 对 ADAPT6 基因进行 N 端(GHEHEHEDANS)与 C 端(GSSC)修饰,合成纯化前体后以 68Ga 标记制备 [68Ga]Ga-NODAGA-ADAPT6。
  • 在 HCC1954(HER2 阳性)与 MDA-MB-468(HER2 阴性)荷瘤小鼠中开展体内代谢与生物分布研究及 Micro-PET/CT 显像。
  • 经伦理批准和知情同意,22 例乳腺癌患者接受 [68Ga]Ga-NODAGA-ADAPT6 PET 显像以评估原发与转移灶的 HER2 表达。

主要发现

  • 示踪剂放化纯度超过 99%,在体内表现出高稳定性。
  • Micro-PET/CT 显示示踪剂在 HCC1954 肿瘤中显著聚集,经曲妥珠单抗阻断 HER2 后聚集明显减少。
  • MDA-MB-468 肿瘤摄取极低。
  • 临床研究中,[68Ga]Ga-NODAGA-ADAPT6 PET 图像显示原发与转移灶摄取程度不一,并与病理分析确定的 HER2 表达状态相关性良好。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Accurate assessment of human epidermal growth factor receptor type 2 (HER2) expression is crucial for diagnosis, treatment planning, and monitoring of breast cancer patients. A 68Ga-labeled tracer based on the albumin-binding domain-derived affinity protein 6 (ADAPT6) was developed to evaluate HER2 expression in breast cancer. METHODS: The gene encoding ADAPT6 was modified with N-terminal (GHEHEHEDANS) and C-terminal (GSSC) extensions to enhance its functionality. The precursor was synthesized, purified, and characterized, followed by radiolabeling with 68Ga to produce [68Ga]Ga-NODAGA-ADAPT6. In vivo metabolism and biodistribution studies were performed in HCC1954 (HER2-positive) and MDA-MB-468 (HER2-negative) tumor-bearing mice. Additionally, with ethical approval and informed consent, 22 breast cancer patients underwent [68Ga]Ga-NODAGA-ADAPT6 PET imaging to assess HER2 expression in primary and metastatic lesions. RESULTS: The tracer was prepared with a radiochemical purity exceeding 99% and demonstrated high stability in vivo. Micro-PET/CT imaging revealed significant accumulation of the radiotracer in HCC1954 tumors, which was markedly reduced after HER2 blockade with trastuzumab. In contrast, MDA-MB-468 tumors showed minimal uptake. In the clinical study, [68Ga]Ga-NODAGA-ADAPT6 PET images displayed varying levels of radiotracer uptake in primary and metastatic lesions, which correlated well with the HER2 expression status determined by pathological analysis. CONCLUSION: [68Ga]Ga-NODAGA-ADAPT6 exhibited excellent pharmacokinetic properties and high specificity for HER2-expressing lesions in PET imaging. These findings highlight its potential as a promising tool for distinguishing different levels of HER2 expression in breast cancer, aiding in personalized treatment strategies.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Tao W, Zhang J, Meng X, et al. Development and clinical evaluation of [68Ga]Ga-NODAGA-ADAPT6 as a novel HER2-targeted PET radiotracer for breast cancer imaging and treatment monitoring. Eur J Nucl Med Mol Imaging. 2025. PMID: 40257612. doi:10.1007/s00259-025-07286-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。